Update Dec 9, 2019: Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 billion
------
The biopharmaceutical company Synthorx designs proteins for targeted therapeutic modulation of tumors and autoimmune disorders.
Synthorx opened for trading at $15.40 after pricing IPO at $11.
The company issued 9.1 million shares
No comments:
Post a Comment